We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+6.86%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.54B
AUM Growth
+$74.3M
Cap. Flow
-$104M
Cap. Flow %
-2.3%
Top 10 Hldgs %
49.79%
Holding
155
New
7
Increased
39
Reduced
61
Closed
13

Top Buys

Rank Stock Value
1
IMCR icon
Immunocore
IMCR
+$37.9M
2
AKRO
Akero Therapeutics
AKRO
+$33.4M
3
BPMC
Blueprint Medicines
BPMC
+$29.6M
4
TMO icon
Thermo Fisher Scientific
TMO
+$20.6M
5
EWTX icon
Edgewise Therapeutics
EWTX
+$19.4M

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$33M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$25.4M
3
ISRG icon
Intuitive Surgical
ISRG
+$24.6M
4
BSX icon
Boston Scientific
BSX
+$18.8M
5
COR icon
Cencora
COR
+$18.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.88%
2 Technology 0.01%
3 Consumer Discretionary 0.01%
4 Communication Services 0.01%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OCS icon
126
Oculis Holding
OCS
$672M
$188K ﹤0.01%
9,700
-4,400
-31% -$80.8K
PTCT icon
127
PTC Therapeutics
PTCT
$6.37B
$186K ﹤0.01%
3,800
– –
GRMN
128
Garmin
GRMN
$46.9B
$177K ﹤0.01%
850
– –
KRYS icon
129
Krystal Biotech
KRYS
$9.88B
$172K ﹤0.01%
1,250
-1,400
-53% -$206K
BIDU icon
130
Baidu
BIDU
$35.8B
$172K ﹤0.01%
2,000
– –
ORCL icon
131
Oracle
ORCL
$331B
$143K ﹤0.01%
654
– –
MLTX icon
132
MoonLake Immunotherapeutics
MLTX
$1.59B
$142K ﹤0.01%
3,000
– –
CYTK icon
133
Cytokinetics
CYTK
$11B
$124K ﹤0.01%
3,741
– –
NVDA icon
134
NVIDIA
NVDA
$5.01T
$119K ﹤0.01%
751
– –
ZTS icon
135
Zoetis
ZTS
$31.6B
$102K ﹤0.01%
657
-2,457
-79% -$390K
MSFT icon
136
Microsoft
MSFT
$2.84T
$101K ﹤0.01%
203
– –
A icon
137
Agilent Technologies
A
$39.1B
$95.1K ﹤0.01%
806
– –
QCOM icon
138
Qualcomm
QCOM
$176B
$71.2K ﹤0.01%
447
– –
BIIB icon
139
Biogen
BIIB
$29.9B
$50.5K ﹤0.01%
402
– –
MTD icon
140
Mettler-Toledo International
MTD
$26.8B
$49.3K ﹤0.01%
42
– –
RXRX icon
141
Recursion Pharmaceuticals
RXRX
$1.57B
$27.9K ﹤0.01%
5,514
-189,538
-97% -$931K
TEM
142
Tempus AI
TEM
$7.69B
$15.1K ﹤0.01%
237
– –
ALT icon
143
Altimmune
ALT
$539M
– –
-1,056,793
Closed -$5.28M
BIO icon
144
Bio-Rad Laboratories Class A
BIO
$8.42B
– –
-21,476
Closed -$5.23M
BRKR icon
145
Bruker
BRKR
$9.2B
– –
-335,288
Closed -$14M
CSTL icon
146
Castle Biosciences
CSTL
$749M
– –
-301,103
Closed -$6.03M
ESPR
147
DELISTED
Esperion Therapeutics
ESPR
– –
-9,694,064
Closed -$14M
EVH icon
148
Evolent Health
EVH
$475M
– –
-614,337
Closed -$5.82M
PCVX icon
149
Vaxcyte
PCVX
$7.89B
– –
-11,290
Closed -$426K
RDY icon
150
Dr. Reddy's Laboratories
RDY
$9.82B
– –
-91,916
Closed -$1.21M
3 4 5
6
7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
AI
Advent International Boston, Massachusetts $4.24B AUM 4.24% 1-Year Est. Return

Bellevue Group's Q2 2025 Portfolio in Review

As of Q2 2025, Bellevue Group held 155 positions worth $4.54B, up 1.7% from $4.46B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group's Q2 2025 filing shows 7 new, 39 increased, 61 reduced and 13 closed positions. Its largest new stake was Blueprint Medicines: 284,900 shares worth $36.5M. The largest sale was Incyte, an estimated $33M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

  • Bellevue Group's largest Q2 2025 buy was Blueprint Medicines: 284,900 shares worth $36.5M.
  • Bellevue Group added most to Immunocore in Q2 2025, an estimated $37.9M increase.
  • Bellevue Group's biggest Q2 2025 reduction was Incyte, cutting an estimated $33M.
  • Bellevue Group fully exited Bruker in Q2 2025, selling an estimated $14M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.54B portfolio in Q2 2025.
  • Bellevue Group opened 7 new positions and closed 13 in Q2 2025.
  • Bellevue Group's portfolio value rose 1.7% quarter-over-quarter to $4.54B.

Based on Bellevue Group's 13F filing for Q2 2025, filed 14 Aug 2025.